Takeda Pharmaceutical (TAK) Other Non-Current Liabilities (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Other Non-Current Liabilities of $6.2 billion for Q2 2026, up 79.2% year-over-year from $3.5 billion in Q2 2025, and down 1.95% quarter-over-quarter from $6.4 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $6.2 billion for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 79.2% year-over-year to $6.2 billion; the TTM figure through Jun 2026 stood at $6.2 billion (up 79.2% YoY), while the FY2026 annual figure was $6.6 billion, up 1119.44% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $6.2 billion, down from $6.4 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $6.4 billion in Q1 2026, with the low at $423.1 million in Q1 2023.
- The 5-year median for Other Non-Current Liabilities is $3.6 billion (2022), against an average of $3.2 billion.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities retreated 25.36% in 2024, then soared 1072.32% in 2026.
- Takeda Pharmaceutical's Other Non-Current Liabilities stood at $3.3 billion in 2022, then retreated by 2.55% to $3.3 billion in 2023, then increased by 13.14% to $3.7 billion in 2024, then increased by 0.67% to $3.7 billion in 2025, then soared by 67.93% to $6.2 billion in 2026.
- Business Quant data shows TAK's Other Non-Current Liabilities at $6.2 billion in Q2 2026, $6.4 billion in Q1 2026, and $3.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.24 Bn |
| Mar 31, 2026 | 6.37 Bn |
| Dec 31, 2025 | 3.72 Bn |
| Sep 30, 2025 | 3.74 Bn |
| Jun 30, 2025 | 3.48 Bn |
| Mar 31, 2025 | 543.11 Mn |
| Dec 31, 2024 | 3.69 Bn |
| Sep 30, 2024 | 3.40 Bn |
| Jun 30, 2024 | 3.63 Bn |
| Mar 31, 2024 | 546.15 Mn |
| Dec 31, 2023 | 3.26 Bn |
| Sep 30, 2023 | 4.55 Bn |
| Jun 30, 2023 | 3.85 Bn |
| Mar 31, 2023 | 423.12 Mn |
| Dec 31, 2022 | 3.35 Bn |
| Sep 30, 2022 | 3.51 Bn |
| Jun 30, 2022 | 3.60 Bn |
| Mar 31, 2022 | 449.16 Mn |
| Dec 31, 2021 | 3.71 Bn |
| Sep 30, 2021 | 3.77 Bn |